Please login to the form below

Not currently logged in
Email:
Password:

Industry veteran Louis Nisbet joins Sygnature board

Brings experience from Roche, Glaxo and SmithKline

Sygnature Louis NisbetSygnature Discovery has appointed Dr Louis Nisbet to its board as a non-executive director.

The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

Following this period, he became an entrepreneur, helping to found companies such as Xenova, Brax and InTouch with Health.

Dr Nisbet's current roles include serving as venture partner with Kurma Life Sciences Partners and chairman of the science park BioCity in Nottingham, UK.

Sygnature's CEO Dr Simon Hirst commented that Dr Nisbet joins the board at a time of growth for the company, which includes the recent addition of in vitro bioscience to its capabilities and enhancing its computational chemistry and informatics capabilities.

“Louis will provide us with advice and guidance as we continue our expansion and evolution as a business,” said Dr Hirst.

1st October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics